|
|
|
Volumn 17, Issue 1 Suppl, 2011, Pages
|
|
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
BLOOD CLOTTING FACTOR 10A;
ENOXAPARIN;
MORPHOLINE DERIVATIVE;
RIVAROXABAN;
THIOPHENE DERIVATIVE;
COST BENEFIT ANALYSIS;
DRUG ANTAGONISM;
ECONOMICS;
HIP ARTHROPLASTY;
HUMAN;
KNEE ARTHROPLASTY;
REVIEW;
UNITED STATES;
VENOUS THROMBOEMBOLISM;
ANTICOAGULANTS;
ARTHROPLASTY, REPLACEMENT, HIP;
ARTHROPLASTY, REPLACEMENT, KNEE;
COST-BENEFIT ANALYSIS;
ENOXAPARIN;
FACTOR XA;
HUMANS;
MORPHOLINES;
THIOPHENES;
UNITED STATES;
VENOUS THROMBOEMBOLISM;
|
|
EID: 80052057158
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (15)
|
|
References (0)
|
